XML 33 R14.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Other Balance Sheet Details | 12 Months Ended
--- | ---
Dec. 31, 2023
Other Balance Sheet Details [Abstract] |
Other Balance Sheet Details | Other Balance Sheet Details Inventory, net, consisted of the following:
| December 31,
(in millions) | 2023 |  | 2022
Raw materials | $ | 21.5 |  |  | $ | 12.0 |
Work in process | 9.7 |  |  | 5.6 |
Finished goods | 12.3 |  |  | 17.5 |
| 43.5 |  |  | 35.1 |
Less inventory reserves | (5.2) |  |  | — |
Total inventory, net | $ | 38.3 |  |  | $ | 35.1 |
Property and equipment, net, consisted of the following:
| December 31,
(in millions) | 2023 |  | 2022
Tenant improvements | $ | 38.1 |  |  | $ | 37.9 |
Scientific equipment | 79.6 |  |  | 58.8 |
Computer equipment | 25.2 |  |  | 21.5 |
Furniture and fixtures | 10.9 |  |  | 6.7 |
| 153.8 |  |  | 124.9 |
Less accumulated depreciation | (83.0) |  |  | (66.3) |
Total property and equipment, net | $ | 70.8 |  |  | $ | 58.6 |
Accounts payable and accrued liabilities consisted of the following:
| December 31,
(in millions) | 2023 |  | 2022
Sales rebates and reserves | $ | 139.3 |  |  | $ | 131.9 |
Accrued employee related costs | 86.2 |  |  | 72.8 |
Current branded prescription drug fee | 45.7 |  |  | 27.5 |
Accrued development costs | 44.3 |  |  | 39.1 |
Current income taxes payable | 24.4 |  |  | 9.0 |
Accounts payable and other accrued liabilities | 108.9 |  |  | 67.3 |
Total accounts payable and accrued liabilities | $ | 448.8 |  |  | $ | 347.6 |
Other long-term liabilities consisted of the following:
| December 31,
(in millions) | 2023 |  | 2022
Noncurrent income taxes payable | $ | 96.0 |  |  | $ | 19.8 |
Noncurrent branded prescription drug fee | 10.3 |  |  | 9.9 |
Total other long-term liabilities | $ | 106.3 |  |  | $ | 29.7 |
The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows.
| December 31,
(in millions) | 2023 |  | 2022
Cash and cash equivalents | $ | 251.1 |  |  | $ | 262.9 |
Restricted cash | 8.0 |  |  | 7.8 |
Total cash, cash equivalents and restricted cash | $ | 259.1 |  |  | $ | 270.7 |

X
- Definition Other balance sheet details. + References No definition available. + Details
Name: | nbix_OtherBalanceSheetDetailsAbstract
Namespace Prefix: | nbix_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration